Proton pump inhibitors have changed the management of acid-related upper gastrointestinal disorders. other effective strategies for reducing upper gastrointestinal morbidity include lifestyle modification, Helicobacter pylori eradication for patients with present or past peptic ulcer disease and infection, and less potent therapy for mild dyspepsia and gastro-oesophageal reflux. Proton pump inhibitors have a definite role in the prevention of recurrence of oesophageal strictures. They can also be used to prevent the ulcerative complications of non-steroidal antiinflammatory drugs in patients at high risk. In Barrett's oesophagus the efficacy of proton pump inhibitors in preventing disease progression and the development of adenocarcinoma is unclear.
Introduction
The discovery of Helicobacter pylori and the introduction of proton pump inhibitors (PPIs) in the 1980s were major advances in our understanding and management of upper gastrointestinal disorders. These advances made surgery for peptic ulcer disease largely obsolete. In Australia, general practitioners and gastroenterologists now prescribe PPIs to the extent that they are in the top 10 drugs, by prescription counts and cost. 1 Prescribing patterns reflect recent changes in the epidemiology of acid-related disorders, failure of a multi-pronged approach to chronic upper gastrointestinal disorders, uncertainty about the prevention of long-term complications and confidence about the relative safety of PPIs.
Clinical pharmacology
Gastric acid secretion by the parietal cells is controlled through food-stimulated and neuroendocrine pathways involving the activity of gastrin, histamine, acetylcholine, and pituitary adenylate cyclase activating peptide. PPIs irreversibly inactivate the final effector in the secretion pathway (gastric hydrogen potassium ATPase in the parietal cell). As PPIs suppress stimulated, as well as basal, acid secretion they are best taken before a meal. They are usually taken once daily as the recovery half-life of gastric acid secretion ranges from 15 to 46 hours. 
Indications
In the long-term management of patients taking PPIs, the initial indication for prescription always needs review. Persistent symptoms may require further investigation. high doses of PPI therapy are used, but further studies are needed to assess these findings.
Gastro-oesophageal reflux disease

Malabsorption
The effect of PPI therapy on the bioavailability of minerals, such as calcium, has been extensively studied. 
Conclusion
The use of PPIs is widespread. Gastro-oesophageal reflux disease is a major indication but it should be addressed with lifestyle modification before acid suppression. 
